NEWS
InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data
InMed Pharmaceuticals (NASDAQ: INM) has announced positive results from a long-term (7 months) preclinical Alzheimer's Disease (AD) study of INM-901, confirming previous short-term (3 months) pilot study findings. The study, conducted using the 5xFAD amyloidosis model, showed improvements in cognitive function, memory, and locomotor activity in INM-901-treated AD groups compared to placebo-treated groups.
Key points:
INM-901-treated AD groups showed positive trends towards behavior similar to untreated disease-free groups
Statistically significant improvements were achieved in certain behavioral criteria
Results supported and improved upon prior short-term pilot study outcomes
Further molecular analyses are ongoing to define mechanisms of action
Development of chemistry, manufacturing, and controls (CMC) is in progress
GLP studies are being planned to support an IND submission
Key points:
INM-901-treated AD groups showed positive trends towards behavior similar to untreated disease-free groups
Statistically significant improvements were achieved in certain behavioral criteria
Results supported and improved upon prior short-term pilot study outcomes
Further molecular analyses are ongoing to define mechanisms of action
Development of chemistry, manufacturing, and controls (CMC) is in progress
GLP studies are being planned to support an IND submission
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1120Followers
71Following
7831Visitors
Follow